Cannabis
PAOG Confirms $300,000 Sales Agreement with Cannabis Cultivation Subsidiary
Sandusky, Ohio–(Newsfile Corp. – February 3, 2021) – PAO Group, Inc. (OTC Pink: PAOG) today confirmed a $300,000 sales agreement executed by the Company’s cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020.
Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (OTC Pink: PURA). The acquisition was made in conjunction with PAOG’s overall strategy to refresh and renew its overall cannabis healthcare industry strategy.
Last year, also in conjunction PAOG’s plan to refresh and renew its overall cannabis healthcare industry strategy, the company with PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT”.
As part of the transaction with PURA, PAOG plans to issue a dividend of one share to PURA shareholders for every one share held of PURA stock. PAOG and PURA anticipate announcing dividend details soon pending the completion of necessary approvals now underway.
Learn more about PAOG at www.paogroupinc.com.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73587
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis2 weeks ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
transfer2 weeks ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan4 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf5 days ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis4 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care